Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACR | P10323 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235361 | 0.87 | MAPT (0.58) | ACRNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL12643803 | 0.86 | MEN1 (0.52) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL14235818 | 0.86 | ACR (0.56) | ACRNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL14235355 | 0.85 | SMN1; SMN2 (0.48) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL14236036 | 0.84 | ADORA3 (0.50) | ACRNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL3222703 | 0.75 | NPC1 (0.53) | NPC1RAB9ATP53SMN1; SMN2ALOX15 | |
| SCHEMBL28617518 | 0.73 | MEN1 (0.59) | ACRNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL14235829 | 0.73 | NPC1 (0.49) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL14213415 | 0.73 | HCAR3 (0.48) | ACRSMN1; SMN2ALPL | |
| SCHEMBL14213418 | 0.73 | HCAR3 (0.50) | ACRNPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | ACR 4331/4885NPC1 2683/4885RAB9A 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.